Pharma Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Geron clarifies license rights for cancer vaccines
February 27th, 2006
Geron Corp. (GERN) provided clarification with respect to license rights granted to third parties to develop cancer vaccines targeting telomerase. On July 15, 2005, Geron announced a worldwide, exclusive license and collaboration agreement with Merck & Co., Inc., (MRK) which includes the grant of rights to Merck to develop anticancer therapies that target telomerase utilizing Merck's vaccine platforms. The agreement also grants Merck an exclusive option to Geron's dendritic cell-based telomerase vaccine. On February 1, 2006, Pharmexa, A/S, Horsholm, Denmark, which acquired GemVax in 2005, issued an announcement describing studies it intends to pursue with a...
Source: Pharma Business Week (2006-02-27)
|
